Filing Flows › Aligos Therapeutics (ALGS) › How it makes money
How Aligos Therapeutics (ALGS) makes money
Aligos Therapeutics (ALGS) made $2.8M of revenue in the third quarter 2026 (Q3 2026), +282% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $2.8M | 100.0% |
| Income tax | $326K | 11.5% |
| Operating cash flow | $1.5M | 51.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $2.8M | +282% |
| Q1 2026 | $2.8M | +810% |
| Q4 2025 | $169K | -72% |
| Q3 2025 | $741K | -41% |
| Q2 2025 | $965K | -9% |
| Q1 2025 | $311K | -55% |
| Q4 2024 | $606K | -10% |
From Aligos Therapeutics' 10-Q filed Nov 6, 2026 (on EDGAR).
Questions
How does Aligos Therapeutics make money?
Aligos Therapeutics (ALGS) made $2.8M of revenue in the third quarter 2026 (Q3 2026), +282% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.